Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Press Bhutan.
Press releases published on October 13, 2025
BioXcel Therapeutics to Ring Nasdaq Closing Bell on October 14 to Celebrate a Transformative Milestone in Neuroscience Innovation
NEW HAVEN, Conn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company pioneering the use of artificial intelligence to develop transformative medicines in neuroscience, announced today that CEO Vimal …
Together We Build: Rentschler Biopharma celebrates construction progress of new buffer media facility, largest single investment at Laupheim site
Symbolic milestone for new buffer media station: Rentschler Biopharma underscores its commitment to the Laupheim headquarters and to the future of Germany and Europe as leading biotechnology hubs Shaping dialogue: Panel discussion held with members of the …
CHAPPER healthcare, AscellaHealth’s Global Pharmaceutical Distributor, Celebrates 50 Years of Global Pharmaceutical Excellence
WATFORD, United Kingdom and BERWYN, Pa., Oct. 13, 2025 (GLOBE NEWSWIRE) -- CHAPPER healthcare, AscellaHealth’s global pharmaceutical wholesaler, distributor, and service provider, proudly celebrates its 50th anniversary—marking five decades of delivering …
Theolytics to Present Ongoing Phase I/IIa OCTOPOD-IV Trial of THEO-260 in Ovarian Cancer at ESMO 2025
THEO-260 is an oncolytic immunotherapy developed for effective targeting of cancer cells and cancer-associated fibroblasts, whilst inducing immune activation in stromal rich tumours UK clinical trial recruitment is on track, and additional international …
HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 13, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) announces results from the FRUSICA-2 registration clinical trial of the fruquintinib and sintilimab …
Qualigen Therapeutics Announces the Official Launch of C10 Cryptocurrency Asset Treasury (DAT) Purchases: Why Is This Pullback the Golden Moment CXC10 Has Been Waiting For?
Carlsbad, CA, Oct. 12, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) today announced the official launch of C10 Cryptocurrency Asset Treasury (DAT) purchases: Why is this pullback the golden moment CXC10 has been …